Synthesis and Anti-Diabetic Activity of an 8-Purine Derivative as a Novel DPP-4 Inhibitor in Obese Diabetic Zücker Rats
DOI: https://doi.org/10.2147/dddt.s450917
IF: 4.3188
2024-04-10
Drug Design Development and Therapy
Abstract:Meriem Chayah, 1– 3 Angélica Luque-González, 1 Verónica Gómez-Pérez, 1 Diego Salagre, 4, 5 Amjad Al-Shdaifat, 6 Joaquín María Campos, 1, 2 Ana Conejo-García, 1, 2 Ahmad Agil 2, 4, 5 1 Department of Medicinal and Organic Chemistry and Excellence Research Unit of Chemistry Applied to Biomedicine and the Environment, Faculty of Pharmacy, University of Granada, Granada, Spain; 2 Biosanitary Institute of Granada (Ibs.granada), SAS-University of Granada, Granada, Spain; 3 Centre for Genomics and Oncological Research, Pfizer/University of Granada/Andalusian Regional Government (GENYO), Granada, Spain; 4 Department of Pharmacology, Faculty of Medicine, University of Granada, Granada, Spain; 5 Federico Oloriz Neuroscience Institute, University of Granada, Granada, Spain; 6 Department of Medicine and Family Medicine, Faculty of Medicine, Hashemite University, Zarqa, Jordania Correspondence: Ahmad Agil; Ana Conejo-García, Email ; Type 2 diabetes mellitus (T2DM) is one of the world's principal metabolic diseases characterized by chronic hyperglycemia. The gut incretin hormones, glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), which has been proposed as a new treatment for T2DM, are extensively metabolized by Dipeptidyl peptidase 4 (DPP-4). Inhibitors of DPP-4 block the degradation of GLP-1 and GIP and may increase their natural circulating levels, favoring glycemic control in T2DM. A novel and potent selective inhibitor of DPP-4 with an 8-purine derived structure ( 1 ) has been developed and tested in vitro and in vivo in Zücker obese diabetic fatty (ZDF) rats, an experimental model of the metabolic syndrome and T2DM to assess the inhibitory activity using vildagliptin as reference standard. ZDF rats were subdivided into three groups (n = 7/group), control (C-ZDF), and those treated with compound 1 (Compound 1 -ZDF) and with vildagliptin (V-ZDF), both at 10 mg/kg/d rat body weight, in their drinking water for 12 weeks, and a group of lean littermates (ZL) was used. ZDF rats developed DM (fasting hyperglycemia, 425 ± 14.8 mg/dL; chronic hyperglycemia, HbA1c 8.5 ± 0.4%), compared to ZL rats. Compound 1 and vildagliptin reduced sustained HbAl1c (14% and 10.6%, P < 0.05, respectively) and fasting hyperglycemia values (24% and 19%, P < 0.05, respectively) compared to C-ZDF group (P < 0.001). Compound 1 and vildagliptin have shown a potent activity with an IC 50 value of 4.92 and 3.21 μM, respectively. These data demonstrate that oral compound 1 administration improves diabetes in ZDF rats by the inhibitory effect on DPP-4, and the potential to be a novel, efficient and tolerable approach for treating diabetes of obesity-related T2DM, in ZDF rats. Keywords: diabetes mellitus type 2, DPP-4 inhibitors, purine derivatives, ZDF rats Diabetes is a major global problem nowadays. It currently affects nearly 537 million people worldwide in 2023, and this number will rise to 700 million in 2045. 1 Among the latest approaches for the treatment of T2DM, the inhibition of the enzyme DPP-4 emerged as an interesting alternative. This approach is based on the key role that DPP-4 has in the inactivation of the two primary endogenous incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP), both secreted from the intestine to stimulate insulin secretion from pancreatic β cells. 2 The incretin effect accounts for at least 50% of the total insulin secreted after ingestion. In addition to its insulinotropic effects, GLP-1 decreases food intake, inhibits glucagon secretion and gastric emptying, and slows the rate of endogenous glucose production. 3 It has also been shown to stimulate β-cell proliferation and to protect them from apoptosis. Both peptides had sparked interest in their therapeutic potential as anti-diabetic agents. However, they are rapidly inactivated by DPP-4 resulting in a half-life of only 1–2 minutes. 4 Therefore, the inhibition of DPP-4 prolongs the half-life and increases the levels of endogenous active GLP-1 and thereby greatly enhances its insulinotropic effect. 5 Currently, DPP-4 inhibitors are firmly established as a treatment for T2DM proving efficacy and better glycemic control leading to a statistically significant long-term reduction in glycated hemoglobin (HbA1c) without risk of hypoglycemia and cardiovascular side effects. 6,7 Thus, several DPP-4 inhibitors, such as vildagliptin, saxagliptin, sitagliptin, alogliptin, or linagliptin (Figure 1), are approved worldwide as monotherapy o -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal